• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment
【24h】

Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment

机译：抗病毒治疗和非治疗期间慢性乙型肝炎患者的健康相关生活质量

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Health-related quality of life (HRQoL) has emerged as an important consideration in the care of patients with chronic hepatitis B (CHB). However, whether benefits from the improved HRQoL that occurs after antiviral treatment or drug discontinuation outweigh the risks of viral relapse is an unanswered question. The aim of this study was to evaluate the HRQoL among patients with CHB during antiviral treatment and withdrawal of treatment. Patients and methods: There were 102 patients who met the enrollment criteria with 54 patients in the treatment group and 48 patients in the discontinuation group. Sociodemographic information was collected. The 36-Item Short-Form Health Survey (SF-36), European Quality of Life-5 Dimensions, and Beck Depression Inventory (BDI) were adopted to evaluate life quality and mental health. Results: In the treatment group, SF-36 showed that the physical functions were significantly increased. In the discontination group, the psychological functions showed improvement. A multivariate regression analysis indicated that baseline SF-36 score was a predictor for improvement in HRQoL (odds ratio =1.17, P =0.003) and baseline BDI score was a factor for remission of depression (odds ratio =0.75, P =0.005) after medical intervention. When the cutoff value of SF-36 score was set at 79.5, the sensitivity and specificity to predict improvement in HRQoL were 82.8% and 74.0%, respectively. When the cutoff value of BDI was found as 8.5, the sensitivity and specificity to predict alleviation of depression were 58.6%, and 76.0%, respectively. Conclusion: Antiviral treatment benefits the physical health of the patients with CHB, while conferring no obvious improvement in their psychological condition. Improved psychological interventions for patients with CHB, especially for those with lower baseline SF-36 scores and higher BDI scores, may improve their quality of life.
机译：简介：与健康相关的生活质量（HRQoL）已成为治疗慢性乙型肝炎（CHB）患者的重要考虑因素。但是，抗病毒治疗或药物停药后改善的HRQoL所带来的收益是否超过病毒复发的风险，这是一个悬而未决的问题。这项研究的目的是评估抗病毒治疗和停药期间CHB患者的HRQoL。患者和方法：符合入组标准的102例患者，治疗组54例，停药组48例。收集了社会人口学信息。通过了36项简短健康调查（SF-36），欧洲生活质量5维度和贝克抑郁量表（BDI）来评估生活质量和心理健康。结果：在治疗组中，SF-36显示身体机能明显增强。在停药组中，心理功能有所改善。多元回归分析表明，基线SF-36评分是HRQoL改善的预测指标（优势比= 1.17，P = 0.003），基线BDI得分是缓解抑郁症的因素（优势比= 0.75，P = 0.005）。医疗干预。当SF-36评分的临界值设为79.5时，预测HRQoL改善的敏感性和特异性分别为82.8％和74.0％。当BDI的临界值为8.5时，预测抑郁缓解的敏感性和特异性分别为58.6％和76.0％。结论：抗病毒治疗有益于慢性乙型肝炎患者的身体健康，而其心理状况并未得到明显改善。改善对CHB患者的心理干预，尤其是那些基线SF-36分数较低和BDI分数较高的患者，可能会改善其生活质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号